Our vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With our robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value radiopharmaceutical intellectual property, we are poised to deliver on the promise of radiopharmaceuticals. www.sofie.com www.twitter.com/sofiebio www.instagram.com/sofiebio Show more Show less
2008
SOFIE raised undisclosed on February 28, 2024
Investors: Trilantic North America